The BIOKÉ webshop is under construction until January 2nd, 2017. We wish you a successful 2017!
Every year BIOKÉ speaks at professional seminars and comes to world wide exhibitions in the life science industry.
Are you eager to meet us? On the left sidebar our events calendar is shown, hope to see you next time!
LEIDEN, April 3, 2017 - BIOKÉ, a business unit of Cell Signaling Technology Europe (CST Europe), and Bethyl Laboratories, Inc. announced that they have signed an agreement allowing BIOKÉ to exclusively distribute Bethyl’s products in the BeNeLux countries, effective immediately.
LEIDEN, March 22, 2017 - BIOKÉ, a business unit of Cell Signaling Technology Europe (CST Europe), and ACEA Biosciences, Inc., a high performance cell analysis platforms manufacturer, announced their partnership to exclusively distribute ACEA’s xCELLigence® Cell Analyzer in the BeNeLux countries, effective immediately.
February 10, 2017, Danvers, MA — Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, was honored with the 2017 CiteAb Award for “PTM Antibody Company of the Year” and for a third year in a row with the award for “Researchers’ Choice.” CST was also a close runner-up for the “Antibody Company of the Year” award. The CiteAb Antibody Awards aim to celebrate the very best suppliers, reagents, and individuals in the research antibody sector, recognizing the efforts that are made to progress science.
January 26, 2017, State College PA - SoftGenetics announced the availability of its new GeneMarkerHTS software for analysis of the Mitochondrial Genome for Forensic and Clinical Research applications from High Throughput Sequencing systems. GeneMarkerHTS is believed to be the first commercially available software developed exclusively for analysis of NGS Mitochondrial sequencing, is applicable in many cases including mass disaster, missing person, as well as clinical disease research and forensic anthropology applications.
January 19, 2017, State College PA - SoftGenetics announced the availability of the latest version of ChimerMarker software. ChimerMarker software, automated chimerism analysis software, integrates speed and accuracy with a biologist‐friendly interface. The software can be used to monitor chimerism levels in both allogeneic and autologous stem cells transplant or hematopoietic stem ...
Gentbrugge, Belgium – October 10, 2016 - Trinean, the leading provider of microfluidic spectrophotometry platforms, today announces the launch of the new DropSense96. Built upon the highly successful DropSense96 platform, the improved features of the new DropSense96 make it superior to any other droplet UV/VIS reader currently on the market...
DANVERS, Mass - November 21, 2016 – Honored as a life science leader at the 2016 Life Science Industry Awards (LSIA), Cell Signaling Technology (CST), a worldwide provider of antibodies, received Best Customer Service for its outstanding commitment to antibody quality and customer satisfaction. The LSIA recognizes .......
LEIDEN, October 24, 2016 - BIOKÉ, a Cell Signaling Technology Europe (CST Europe) company, and ACEA Biosciences, Inc., a high performance cell analysis platforms manufacturer, announced their partnership to exclusively distribute ACEA’s NovoCyte™ Flow Cytometer in the BeNeLux countries, effective immediately.
September 1, 2016 - NEW YORK (GenomeWeb) – Horizon Discovery announced that it has partnered with Roche subsidiary Ventana Medical Systems to develop and commercialize cell line derivative material for use as immunohistochemistry (IHC) reference standards in cancer tissue diagnostics.
June 13, 2016 - Cell Signaling Technology (CST), CST, a worldwide provider of antibodies, is providing four high school juniors from Boston North Shore communities—Gloucester, Lynn, Peabody and Salem—with $10,000 each to pursue a college education in a science-related program.
April 12, 2016 - Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, released four new monoclonal antibodies relevant to the rapidly growing fields of immunometabolism and tumor immunology.
February 16, 2016 - EMQN integrates Trinean’s DropSense™ into its standards QC procedures and quality assessment schemes for Molecular Genetic Labs
January 12, 2016 - New products use significantly less plastic and recyclable packaging, while delivering best-in-class performance for nucleic acid purification.
April 14, 2016 - Novel target enrichment technology, compatible with low input amounts from challenging sample types, uses a one-day workflow
February 1, 2016 - Cell Signaling Technology (CST) CST was honored today with the 2016 CiteAb® Awards for “Researcher’s Choice” and for a second year in a row “Antibody Company of the Year.”. As a company of scientists, we are humbled and honored to have our efforts....
November 23, 2015 - Nestled between chickpea pasta and apartments for Los Angeles' homeless on Time magazine's list of the year's 25 best inventions is Fluidigm's Juno. The system cuts the time it takes to amplify DNA down to a handful of hours, Time says.
NOVEMBER 3, 2015, NATIONAL HARBOR, MD (US BUSINESS WIRE) Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, announced today the release of 6 new monoclonal antibodies (mAb) for tumor immunology research. This announcement was made at the 30th annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD November 4-8th, 2015.
LEIDEN, October 8, 2015 - BIOKÉ, a Cell Signaling Technology Europe (CST Europe) company, and Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Company”), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, announced that they have signed an exclusive agreement allowing BIOKE to distribute Horizon’s reference standards in The Netherlands, effective as of today.
June 25, 2015 - Fluidigm has launched the Callisto system, a fully automated and programmable microfluidic cell culture system that integrates multifactorial dosing in 32 individual chambers for simultaneous cell culture. This innovative new platform will revolutionize the way cell biologists develop in vitro cell models.
BILLERICA, Mass. — April 20, 2015 — RainDance Technologies, Inc., a genomics tools company simplifying the analysis of complex genetic diseases, today announced global availability of the ThunderBolts Myeloid Panel, a next-generation sequencing (NGS) research assay designed to rapidly detect and cost-effectively analyze genetic mutations associated with AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndromes), MPN (Myeloproliferative Neoplasms) and other myeloid cancer research.